On June 23, the National Engineering Laboratory for Pharmacogenetics and Protein Screening and the editorial departments of the Journal of Chinese Immunology and the Journal of Clinical Immunology and Hepatology Diseases, jointly organized the First International Forum on Biotechnology and Cellular Drugs.
Professor Tian Zhigang, the chairman of the Chinese Immunology Society and an academician of the Chinese Academy of Engineering, gave a keynote report entitled "Tumor immunotherapy Based on NK Cells." More than 160 scientists and technicians from internationally renowned research institutes and companies such as the American National Institutes of Health, the Chinese Academy of Sciences, the Ford Medical University of the United States, the University of Illinois, Peking University, the University of Science and Technology of China, the Northeast Normal University and ACRO Biosystems as well as the China Harbor Biomed Group engaged in the research and development of biotechnology drugs such as immune cells and stem cells participated in the conference. Among them, 19 experts and scholars made academic reports.
(From News Center, translated by Liu Wei, revised by Chen Yanxu)
